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Abstract		Role	of	SARM1	Inactivation	in	Chronic	Immune-Mediated	Central	Nervous	System	Inflammation		By	Kenneth	Edward	Viar,	B.S.	A	thesis	submitted	in	partial	fulfillment	of	the	requirements	for	the	degree	of	Master	of	Science	at	Virginia	Commonwealth	University.		Virginia	Commonwealth	University,	2019		Director	of	Thesis:	Unsong	Oh,	M.D.,	Department	of	Neurology			 SARM1	is	an	injury-induced	nicotinamide	adenine	dinucleotide	nucleosidase	(NADase)	that	was	previously	shown	to	promote	axonal	degeneration	in	response	to	traumatic,	toxic,	and	excitotoxic	stressors.	This	raises	the	question	of	whether	a	SARM1-dependent	program	of	axonal	degeneration	is	central	to	a	common	pathway	contributing	to	disease	burden	in	neurological	disorders.	The	degree	to	and	mechanism	by	which	SARM1	inactivation	decreases	the	pathophysiology	of	such	disorders	is	of	interest	to	establish	the	rationale	to	pursue	SARM1	as	a	therapeutic	target.	In	this	study,	we	compare	the	course	and	pathology	of	experimental	autoimmune	encephalomyelitis	(EAE)	in	Sarm1-knockout	(KO)	mice	and	wild-type	littermates	to	test	the	contribution	of	SARM1-dependent	axonal	degeneration	specifically	in	the	context	of	chronic,	immune-mediated	central	nervous	system	(CNS)	inflammation.	The	question	of	whether	SARM1	loss	in	Sarm1-KO	mice	would	inhibit,	promote,	or	have	a	negligible	impact	on	EAE-induced	axonal	degeneration	and	more	broadly	CNS	inflammation	was	explored	using	a	variety	of	analyses:	quantification	of	clinical	score	in	a	chronic	EAE	model,	CNS	immune	infiltrate	profile,	axon	initial	segment	
 vii 
morphology	in	layer	V	cortical	neurons,	axonal	transport	disruption	and	transection	in	the	lumbar	spinal	cord.	Additionally,	we	have	proposed	a	method	for	detecting	SARM1	activation	in	situ	using	a	novel	SARM1-mCitrine	bimolecular	fluorescence	complementation	(BiFC)	technique.	Successful	implementation	of	such	a	molecular	tool	would	allow	for	a	detailed,	mechanistic	approach	to	enhance	our	understanding	of	upstream	intracellular	signals	that	trigger	SARM1	activation.		 	
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Introduction	Multiple	sclerosis	(MS)	is	a	chronic	inflammatory	and	neurodegenerative	disease	affecting	approximately	2.5	million	people	worldwide	with	over	400,000	to	900,000	in	the	US	alone		(Walin	et	al.,	2019).	While	the	specific	cause	of	MS	is	unknown,	it	is	believed	to	be	influenced	by	both	genetic	and	environmental	factors	that	lead	to	aberrant	immune	responses	and	subsequent	neuro-axonal,	astrocyte,	and	oligodendrocyte	damage	within	the	CNS.	MS	imposes	a	significant	burden	on	society	due	to	the	high	costs	of	treatments	and	limited	employment	opportunities	patients	experience	with	disease	progression.	Clinical	signs	of	MS	usually	begin	between	20	to	40	years	of	age	and	incidence	is	nearly	3-fold	more	common	in	females	than	males	(Dendrou	et	al.,	2015).		From	onset,	there	are	multiple	disease	courses	and	heterogeneous	clinical	manifestations.	The	four	major	clinical	courses	are:	relapsing-remitting	MS	(RRMS),	secondary	progressive	MS	(SPMS),	primary	progressive	MS	(PPMS),	and	progressive	relapsing	(PRMS).	The	first	manifestation	of	disability	prior	to	definitive	diagnosis	of	MS	is	referred	to	as	clinically	isolated	syndrome	(CIS).	Approximately	85%	of	patients	initially	experience	RRMS	characterized	by	intermittent	recurrence	of	neurological	deficits	lasting	days	or	weeks	with	often	complete	or	near	complete	recovery	(Dargahi	et	al.,	2017).	However,	over	time	this	course	of	relapsing	clinical	disease	transitions	to	gradual	progression	of	symptoms,	leading	to	accumulation	of	long-term	disability	in	about	60%	of	individuals	that	are	initially	diagnosed	with	RRMS.	When	these	disabilities	advance	in	the	absence	of	inflammatory	relapses	with	no	recovery,	the	patient	has	entered	into	the	secondary	progressive	phase	of	MS.	PPMS	accounts	for	a	minority	of	patients	and	is	characterized	by	continuous	disease	progression	for	more	than	1	year	in	the	absence	of	
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relapses.	Finally,	while	rare,	PRMS	is	characterized	by	continuous	disease	progression	from	onset	with	added	acute	relapses	and	periods	of	continuous	progression	between	relapses	(Filippi	et	al.,	2018).		The	pathological	hallmark	of	MS	is	the	formation	of	multiple	demyelinating	lesions	and	astrocytic	scaring	in	the	CNS	that	are	characterized	by	the	breakdown	of	the	blood-brain	barrier	(BBB)	resulting	from	pro-inflammatory	cytokines.	Inflammation	is	present	at	all	stages	of	MS,	but	is	more	pronounced	in	early	relapsing	stages	that	are	characterized	by	repetitive	infiltration	of	peripheral	immune	cells.	Immune	infiltrates	together	with	resident	activated	microglia	and	astrocytes,	are	thought	to	contribute	to	oligodendrocyte	injury,	demyelination	and	neuro-axonal	injury	through	cell	contact-dependent	and	independent	mechanisms.	In	contrast,	progressive	stages	of	tissue	injury	are	largely	due	to	oxidative	stress	promoted	by	local	immune	cell	activation	(microglia	and	macrophage),	mitochondrial	dysfunction,	extracellular	free	iron	accumulation,	loss	of	myelin	trophic	support,	ionic	imbalances,	altered	glutamate	homeostasis,	the	failure	of	neuroprotective	and	regenerative	mechanisms,	and	a	pro-inflammatory	environment.	This	collectively	leads	to	chronic	inflammation-induced	CNS	axonal	degeneration	with	atrophy	of	the	grey	and	white	matter	(Filippi	et	al.,	2018).	New	and	existing	demyelinating	lesions	are	visualized	using	magnetic	resonance	imaging	(MRI),	which	has	become	a	key	diagnostic	tool	for	diagnosing	MS	and	monitoring	disease	progression	and	response	to	disease-modifying	therapies	(DMTs).	A	second	diagnostic	tool	for	a	positive	MS	diagnosis	is	the	presence	of	oligoclonal	bands	in	cerebrospinal	fluid	(CSF).	MS	relapses	were	once	thought	to	be	primarily	mediated	by	aberrantly-activated,	CNS-specific	effector	T	cells	that	traffic	into	the	CNS	causing	neuro-axonal	injury,	
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demyelination,	and	glial	activation.	We	now	understand	the	underlying	immune	pathophysiology	of	MS	to	be	much	more	complicated,	as	it	involves	many	bidirectional	interactions	and	secretion	of	inflammatory	mediators	between	immune	cell	types	from	the	periphery	as	well	as	resident	glia	of	the	CNS	(Filippi	et	al.,	2018).	This	inflammatory	milieu	can	disrupt	the	BBB	and	allow	autoreactive	immune	cells	in	peripheral	circulation	access	to	the	CNS.	While	the	majority	of	autoreactive	T	cells	are	eliminated	during	the	process	of	thymic	maturation,	a	low	frequency	of	nonregulatory	T	cells	escape	and	are	present	even	in	healthy	individuals	(Kaiko	et	al.,	2008).	These	naïve,	autoreactive	T	cells	that	recognize	CNS	antigens	have	the	potential	to	become	activated	and	proliferate	once	it	has	encountered	its	cognate	antigen.	CD4+	T	helper	17	cells	(TH17	cells)	are	critical	regulators	of	MS	disease	activity	and	are	speculated	to	contribute	to	direct	injury	of	oligodendrocytes	and	neurons	(van	Langelaar	et	al.,	2018).	However,	CD8+	T	cells	are	found	in	higher	frequency	than	CD4+	in	the	MS	brain	and	their	numbers	correlate	with	axonal	damage	(Frischer	et	al.,	2009).	B	cells	also	have	a	significant	role	in	the	development	of	MS	relapses.	It	is	likely	through	cellular	immune	interactions	and	a	litany	of	inflammatory	mediators	(IL-6,	GM-CSF,	TNF	and	lymphotoxin-α)	that	drive	aberrant	TH17/TH1	and	myeloid	cell	responses	(Bar-Or	et	al.,	2010).	The	prominent	role	of	B	cells	in	MS	pathology	is	highlighted	by	the	fact	that	B-cell-targeting	therapies,	such	as	antibodies	directed	against	CD20	(pro-B	phase	B-lymphocyte	antigen	20),	were	effective	at	reducing	MS	disease	activity	(Palanichamy	et	al.,	2014).	However,	the	administration	of	anti-CD20	antibodies	does	little	to	reduce	the	presence	of	oligoclonal	bands	in	CSF.	Therefore,	this	therapy	likely	ameliorates	symptoms	by	downregulation	of	pro-inflammatory	mediators	(Filippi	et	al.,	2018).	This	has	offered	improved	outcomes	for	patients	suffering	from	PPMS	that	were	otherwise	resistant	to	
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immune	ablation	therapies.	Anti-CD20	antibody	therapy	(ocrelizumab)	and	other	disease	modifying	therapies	(DMTs)	were	initially	tested	using	an	animal	models	of	MS	known	as	experimental	autoimmune	encephalomyelitis	(EAE)	(Palanichamy	et	al.	2014).	EAE	has	been	optimized	as	the	primary	model	for	the	study	and	development	of	new	therapeutic	strategies	in	MS	(Kaskow	et	al.,	2018).	EAE	can	be	actively	induced	or	passively	transferred.	Active	EAE	relies	on	the	priming	of	encephalitogenic	T	cells	with	myelin	antigens	emulsified	in	complete	Freund’s	adjuvant	(CFA)	and	in	many	cases	supplemented	with	an	injection	of	pertussis	toxin.	This	combination	disrupts	the	BBB,	which	normally	impedes	migration	of	autoreactive	lymphocytes	into	brain	parenchyma.	Some	encephalitogenic	antigens	include:	myelin	oligodendrocyte	glycoprotein	(MOG),	proteolipid	protein	(PLP),	myelin	basic	protein	(MBP),	myelin-associated	glycoprotein	(MAG),	and	myelin-associated	oligodendrocytic	basic	protein	(MOBP).	MOG	has	emerged	as	an	important	target	in	MS	because	MOG-reactive	T	cells	are	detected	at	higher	levels	in	MS	patients	(Raddassi	et	al.,	2011).	MOG35-55	is	the	immunodominant	peptide	for	MOG-induced	EAE	in	C57BL/6	mice	(Encinas	et	al.,	1999).	Because	many	gene-specific	knockout	mice	have	been	generated	on	the	C57BL/6	background,	MOG-induced	EAE	has	become	a	popular	disease	model	to	study	MS	(Glatigny	et	al.,	2018).	While	not	a	perfect	model	of	MS,	EAE	does	share	many	pathological	characteristics	with	MS.	The	primary	inflammatory	feature	of	EAE,	caused	through	dysfunction	of	the	BBB	and	aberrant	activation	of	the	immune	system	provokes	a	similar	assortment	of	neurodegenerative	symptoms.	Axonal	injury	is	among	the	most	notable,	and	has	been	associated	with	inflammation	in	all	MS	stages	(Frischer	et	al.,	2009).	The	formation	of	axonal	spheroids	and	transected	axons	has	been	shown	to	occur	early	in	disease	and	is	a	
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major	determinant	of	disability	accumulation	(Trapp	et	al.,	1998;	Vogt	et	al.,	2009).	Disruption	of	functional	domains	of	myelinated	axons	can	also	observed	in	both	EAE	and	MS	(Clark	et	al.,	2016;	Griggs	et	al.,	2017).	The	CNS	does	possess	the	capacity	for	repair	and	remyelination,	which	in	early	relapsing-remitting	stages	can	contribute	to	full	clinical	remission.	However,	once	an	axon	is	completely	severed,	repair	mechanisms	are	insufficient	(Ellwardt	et	al.,	2014).		Current	therapies	largely	focus	on	immunomodulatory	or	immunosuppressive	actions	that	have	been	shown	to	improve	outcomes	in	early	relapsing	remitting	forms	of	MS	(Ellwardt	et	al.,	2014).	However,	immune	ablation	in	progressive	courses	of	MS	is	less	effective,	necessitating	novel	approaches	to	improve	and	diversify	treatment	options.	With	axonal	degeneration	identified	as	a	major	determinant	of	disability	accumulation,	targeting	the	underlying	cellular	mechanisms	that	initiate	this	process	has	the	potential	to	mitigate	disease	burden,	slow	progression,	and	thus	improve	outcomes	for	those	with	progressive	MS.	(Barkhof	et	al.,	1999;	Trapp	et	al.,	1998)		This	begins	with	understanding	how	the	mechanisms	behind	current	models	of	Wallerian	degeneration	relate	to	CNS	inflammatory	disorders.	SARM1	(sterile	alpha	and	TIR	motif-containing	1)	and	nicotinamide	mononucleotide	adenylyltransferase	(NMNAT)	are	proteins	involved	in	NAD	(Nicotinamide	adenine	dinucleotide)	metabolism	and	established	opposing	elements	in	programmed	axonal	degeneration	(Mack	et	al.,	2001;	Osterloh	et	al.,	2012).	Because	NAD	is	a	cofactor	found	in	all	cells	and	is	essential	to	redox	metabolism	during	beta	oxidation,	glycolysis	and	oxidative	phosphorylation,	its	concentration	within	the	cell	must	be	closely	regulated	and	kept	within	a	narrow	physiological	range.	NMNAT	catalyzes	the	last	step	in	converting	nicotinamide	
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mononucleotide	(NMN)	to	NAD,	both	in	the	de	novo	synthesis	and	salvage	pathways.	A	transgenic	form	of	NMNAT,	originally	characterized	in	the	“Wallerian	degeneration	slow”	(Wlds)	mouse,	was	shown	to	confer	enhanced	axonal	survival	following	axonal	injury,	but	the	exact	mechanism	behind	this	effect	is	not	yet	fully	understood	(Brazill	et	al.,	2017).	The	role	of	NMNAT	in	regards	to	enhanced	NAD	biosynthetic	capacity	is	well	established,	which	was	initially	thought	to	simply	override	the	NAD-cleaving	activity	of	SARM1	thus	preventing	the	local	metabolic	stress	leading	to	programmed	axonal	degeneration	(Girouard	et	al.,	2018).	However,	recent	work	involving	NMNAT	overexpression	in	neurons	has	shown	that	NMNAT-mediated	axon	protection	may	also	hinge	on	its	ability	to	block	SARM1	signaling	through	an	enzyme-independent,	chaperone	function	as	it	has	been	shown	to	confer	neuroprotection	without	altering	NAD	synthesis	(Brazill	et	al.,	2017).		While	the	exact	nature	and	individual	contribution	of	each	of	these	inhibitory	mechanisms	is	yet	to	be	determined,	it	is	clear	that	NMNAT	acts	upstream	of	SARM1	to	promote	neuronal	maintenance	and	that	SARM1	activation	triggers	axon	degeneration	locally	via	NAD	destruction.		Increased	NAD	levels	through	altered	NMNAT	activity,	as	in	the	Wlds	mouse,	and	
Sarm1	deletion	are	among	the	most	characterized	methods	to	delay	Wallerian	degeneration.	Because	SARM1	deletion,	and	not	Wlds	expression,	resulted	in	longer-lived	neuroprotection	in	mouse	models	of	severe	axonopathy,	SARM1	depletion	appears	to	have	analytical	and	therapeutic	advantages	over	Wlds	(Gilley	et	al.,	2017).	This	warrants	a	closer	look	at	the	four	functional	domains	of	SARM1	(Figure	6B):	a	mitochondrial	localization	signal	(MLS),	an	autoinhibitory	N-terminus	region	consisting	of	armadillo/HEAT	motifs	(ARM),	two	sterile	alpha	motifs	(SAM)	responsible	for	multimerization,	and	a	C-terminus	
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Toll/Interleuken-1	receptor	(TIR)	domain.	Under	healthy	conditions,	SARM1	exists	as	an	inactive	dimer	with	the	two	ARM	domains	preventing	the	association	of	adjacent	TIR	domains	that	is	required	for	NADase	activity	(Figure	6D)	(Gerdts	et	al.,	2013;	Summers	et	al.,	2016).	Following	axonal	injury,	inhibition	is	removed	and	TIR-mediated	NADase	activity	is	restored	(Figure	6E).	SARM1	NADase	activity	was	found	to	be	essential	in	the	initiation	of	axonal	degeneration	following	axotomy	and	later	in	traumatic,	toxic,	and	excitotoxic	injury.	This	raises	the	possibility	that	a	SARM1-dependent	program	of	axonal	degeneration	could	be	central	to	a	common	pathway.	Therefore,	demonstrating	the	role	of	SARM1	in	axonal	pathology	associated	with	CNS	inflammation,	in	which	a	similar	milieu	of	inflammatory	stressors	is	observed,	would	identify	SARM1	as	an	obstacle	to	axonal	protection	in	MS	and	other	neuroinflammatory	disorders.		Central	to	that	goal	would	be	a	method	to	observe	the	neuroinflammatory	conditions	of	the	EAE	model	in	the	absence	of	functional	SARM1	protein.	A	SARM1	global-knockout	mouse	(B6.129X1-Sarm1tm1Aidi/J)	was	developed	with	congenic,	targeted	mutations	in	exons	3-6,	rendering	it	inactive	(Kim	et	al.,	2007).	With	this	mouse	model,	we	pursued	our	first	aim	to	define	the	effect	that	SARM1	inactivation	had	on	axonal	pathology	in	the	context	of	chronic,	immune-mediated	CNS	inflammation.	First,	we	sought	to	establish	a	difference	in	how	Sarm1-KO	and	wild-type	mice	responded	to	neuroinflammatory	insults	by	scoring	the	motor	deficits	that	resulted	from	EAE	disease	activity.	Then,	shift	to	characterizing	the	mechanism	by	which	loss	of	SARM1	mediated	any	such	difference.	Analyzing	CNS	immune	infiltrate	profiles	of	Sarm1-KO	and	wild-type	mice	during	EAE	was	an	important	first	step.	Because	SARM1	is	expressed	in	neurons	as	well	as	immune	cells,	it	remained	to	be	clarified	whether	any	clinical	effect	would	be	attributable	to	loss	of	
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neuronal	SARM1,	immune	cell	SARM1	or	both.	Next,	we	measured	the	differences	in	axon	initial	segment	(AIS)	number	and	length	in	layer	V	cortical	neurons	in	Sarm1-KO	compared	to	wild-type	littermates.	Then,	quantified	axonal	pathology	within	the	lumbar	spinal	cord	during	EAE	by	looking	at	axonal	transport	disruptions	as	well	as	transection.	We	hypothesized	that	there	would	be	a	reduction	in	axonal	pathology	observed	in	Sarm1(-/-)	mice	induced	with	experimental	autoimmune	encephalomyelitis	(EAE)	when	compared	to	wild-type	Sarm1(+/+)	littermates,	thereby	confirming	the	contribution	of	SARM1	to	axonal	degeneration	in	CNS	inflammatory	disorders.		Our	second	aim	was	to	demonstrate	a	molecular	technique	able	to	screen	for	SARM1-activation	in	situ	using	bimolecular	fluorescence	complementation.	Successful	implementation	of	such	a	molecular	tool	would	allow	for	a	detailed,	mechanistic	approach	to	enhance	our	understanding	of	upstream	intracellular	signals	that	trigger	SARM1	activation.	Because	SARM1	dimerization	and	association	of	two	TIR	domains	is	an	essential	step	in	activation,	two	SARM1	proteins	each	with	a	different	complementary	fragment	of	mCitrine	fused	to	the	TIR	domain	can	be	used	to	signify	when	this	activation	occurs.	This	is	based	on	complementation	between	N-terminal	and	C-terminal	fragments	(–N172	and	–C67)	of	monomeric	Citrine,	a	variant	of	green	fluorescent	protein	(GFP).	These	fragments	are	individually	non-fluorescent,	but	when	brought	in	close	proximity	to	one	another	fluorescence	is	restored	(Hu et al., 2005).	This	is	accomplished	in	situ	when	two	SARM1-BiFC	plasmids	coding	for	the	complementary	fragments	of	Citrine	fused	to	the	TIR	domains	are	transfected	into	neurons,	but	only	when	brought	in	close	proximity	to	one	another	as	in	the	case	during	SARM1	activation.	Thus,	our	second	aim	goals	were	to	design,	transfect,	
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and	confirm	expression	of	SARM1-mCitrine	fusion	proteins	using	HEK293	cells	and	western	blot.			
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Methods	
Animals		
Sarm1	KO	mice	(B6.129X1-Sarm1tm1Aidi/J)	were	obtained	from	Jackson	Laboratories	and	maintained	on	a	C57BL/6J	(Kim	et	al.,	2007).	A	colony	of	Sarm1	KO	mice	were	maintained	locally	by	heterozygous	mating	to	produce	homozygous	Sarm1	knockout		[Sarm1(-/-)],	heterozygotes	[Sarm1(+/-)],	and	wild-type	littermates	[Sarm1(+/+)].	In	addition,	Thy1-YFP-H	mice	[B6Cg-TgN	(Thy1-YFP-H)2Jrs,	Jackson	Laboratories	stock	number	003782]	from	an	established	colony	maintained	locally,	were	crossed	with	Sarm1-KO	mice	to	produce	Sarm1(-/-)/Thy-1-YFP(+)	and	Sarm1(+/+)/	Thy-1-YFP(+)	in	select	experiments.	Both	adult	males	and	females	were	included,	all	between	6	–	12	weeks	of	age	unless	otherwise	stated.	Animals	were	housed	in	an	Assessment	and	Accreditation	of	Laboratory	Animal	Care	(AAALAC)	accredited	vivarium	of	Virginia	Commonwealth	University	on	an	alternating	12-hour	light	and	dark	cycle	with	food	and	water	provided	ad	libitum.	All	studies	involving	mice	were	conducted	in	accordance	with	the	methods	outlined	in	protocols	approved	by	the	Institutional	Animal	Care	and	Use	Committee	of	Virginia	Commonwealth	University.			
Experimental	autoimmune	encephalomyelitis		An	emulsion	containing	myelin	oligodendrocyte	glycoprotein	(MOG33-55,	AnaSpec)	peptide	and	Complete	Freund’s	adjuvant	(CFA;	Chondrex)	supplemented	with	2mg/ml	of	
Mycobacterium	Tuberculosis	(Invitrogen	Life	Technologies)	was	prepared	using	glass	syringes	and	emulsifying	needle	until	viscous	and	white	in	color.	Mice	were	injected	subcutaneously	at	two	sites	over	the	shoulder	with	100	µl	of	emulsion	(50	µl	per	site)	
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containing	200	µg	MOG33-55.	This	was	supplemented	with	an	intraperitoneal	(i.p.)	injection	of	300	ng	pertussis	toxin	(PT;	List	Biological	Labs)	in	200	µl	PBS	delivered	at	time	of	immunization	with	an	additional	PT	injection	48	hours	later.	Clinical	symptoms	of	disease	and	animal	weight	were	recorded	from	day	5	post-immunization	to	day	42	(Clark	et	al.,	2016).	Absorbent	bedding	and	moist	food	were	introduced	when	the	mice	reached	a	clinical	score	of	3	or	more	and	given	daily	subcutaneous	saline	injections	when	above	3.5.	The	clinical	scores	were	applied	as	previously	described	(Louveau	et	al.,	2018),	based	on	the	following	criteria:		A	score	of	0	indicated	the	mouse	was	clinically	normal.			A	score	of	1	was	characterized	by	complete	loss	of	muscle	tone	in	tail.	A	score	of	0.5	was	given	for	incomplete	loss	of	muscle	tone	in	tail.		A	score	of	2	was	characterized	by	mild	hind	limb	paresis.	The	animal	demonstrated	decreased	dexterity/coordination	with	hind	limbs	and	was	unable	to	right	itself	immediately	if	turned	on	back.	Animal	gait	was	mostly	normal,	but	uncoordinated	at	times.	A	mouse	cage	wire	was	used	to	determine	the	degree	of	hind	limb	impairment	by	placing	mouse	on	flat	portion	parallel	with	the	wire	bars	and	then	hind	limbs	repetitively	suspended	and	dropped	onto	wire	allowing	approximately	3	seconds	between	5	separate	tests.	If	one	or	both	of	the	hind	legs	slipped	through	cage	wire	in	3	out	of	5	tests,	then	a	score	of	2	was	given.	A	score	of	1.5	was	given	for	a	mouse	that	demonstrated	some	degree	of	hind	limb	impairment,	but	fell	below	the	3-out-of-5	threshold.	The	observed	position	of	the	hindlimbs	while	suspended	aided	in	this	distinction.	A	mouse	that	has	a	score	greater	than	1	does	not	demonstrate	the	natural	widened-hindlimb	stance	that	a	clinically	normal	
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mouse	would	while	suspended,	but	instead	holds	legs	and	feet	more	centered	below	hips.	If	an	animal	displayed	this	altered,	narrow	hindlimb	stance	while	suspended	and	was	unable	to	prevent	its	legs	from	falling	though	the	cage	in	at	least	1	or	2	of	the	5	tests,	then	a	score	of	1.5	was	given.			A	score	of	3	was	mainly	characterized	by	severe	hind	limb	impairment	or	paralysis.	This	was	evident	in	abnormal	gait	and	commonly	unkept	coat	due	to	difficulties	with	grooming.	A	mouse	cage	wire	was	used	to	determine	the	degree	of	hind	limb	impairment	by	placing	the	mouse	on	the	flat	portion	of	the	cage	wire	with	bars	running	parallel	with	the	mouse’s	body	and	inverting	it.	The	cage	wire	was	maintained	in	inverted	position	for	3	seconds.	To	ensure	the	animal’s	safety,	this	test	was	conducted	over	top	of	the	cage	with	a	free	hand	below	to	catch	the	mouse	in	the	event	that	it	could	not	support	itself.	This	test	was	repeated	twice.	If	the	mouse	was	unable	to	support	itself	for	a	period	of	3	seconds	both	times,	a	score	of	3	was	given.	If	the	animal	fell	during	one	test	and	supported	itself	for	a	minimum	of	3	seconds	during	the	other,	or	if	the	animal	was	able	to	support	itself	for	a	period	of	3	seconds	hanging	solely	by	fore	limbs,	a	score	of	2.5	was	given.	If	it	was	apparent	that	the	animal	was	unable	to	adequately	grip	the	bars	when	slightly	tilted,	the	inversion	test	was	not	necessary	and	additional	testing	was	used.		A	score	of	4	is	characterized	by	complete	hind	limb	paralysis	and	forelimb	paresis.	The	animal’s	hindlimbs	were	observed	to	be	completely	immobilized,	but	was	still	able	to	move	with	use	of	forelimbs,	and	commonly	displays	unkept	coat	due	to	difficulties	with	grooming.	If	the	animal	was	capable	of	minor	hindlimb	movement	(“paddling”)	while	still	able	to	effectively	move	with	the	use	of	its	forelimbs,	then	a	score	of	3.5	is	given.		
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	A	score	of	5	was	characterized	by	paralysis	of	all	limbs	and	moribund	state.	The	animal	was	immobile	and	presented	with	irregular	breathing.	If	an	animal	displayed	a	score	of	5,	it	was	euthanized.	A	score	of	4.5	was	given	if	the	animal’s	muscles	in	legs	and	lower	back	showed	signs	of	atrophy,	but	was	still	capable	of	limited	locomotion	and	breathing	normally.			
Tissue	fixation	and	cryoprotection		
	Mice	were	given	a	lethal	dose	of	anesthetics	by	intraperitoneal	(i.p.)	injection	of	a	2.5%	solution	of	avertin	(2,2,2	tribromoethanol,	Sigma-Aldrich)	(0.016	mL/g	body	weight).	Mice	were	then	transcardially	perfused	first	with	room-temperature	normal	saline	followed	immediately	by	4%	paraformaldehyde.	The	entire	CNS	was	collected,	cryoprotected	with	30%	sucrose,	and	frozen	in	Tissue-Plus®O.C.T.	compound	(Thermo	Fisher	Scientific).	Fixed,	frozen	brains	and	spinal	cords	were	then	serially	sliced	into	30-μm	or	20-μm-thick	sections	with	a	cryostat	(Leica),	collected	onto	Superfrost™	Plus	slides	(Thermo	Fisher	Scientific),	and	stored	in	manual-defrost	freezer	at	-20°C	(Benusa	et	al.,	2017;	da	Mesquita	et	al.,	2018).	
	
Antibodies	Axon	initial	segments	(AISs)	were	visualized	using	mouse	monoclonal	antibodies	directed	against	ankyrin-G	(AnkG;	Millipore;	N106/36,	1:500)	Neurons	were	identified	using	the	NeuN	antibody	(Millipore;	1:500).	To	assess	axon	spheroid	formation,	antibodies	directed	against	amyloid	precursor	protein	(APP;	ThermoFisher;	#36-6900;	1:400)	was	used.	All	secondary	antibodies	were	obtained	from	Invitrogen	Life	Technologies	(AlexaTM	Fluor)	and	
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used	at	a	dilution	of	1:500.	In	all	instances,	DAPI	(4′,6-diamidino-2-phenylindole;	Invitrogen)	was	used	as	a	nuclear	stain.				For	immunoblot	analysis	of	recombinant	SARM1-mCitrine	fusion	proteins,	either	a	mouse	monoclonal	antibody	directed	against	human	SARM1	(Biolegend;	#696602;	1:250)	or	rabbit	monoclonal	antibody	directed	against	green	fluorescent	protein	(Novus	NB600-308SS;	1:1000)	were	used.	This	was	followed	by	the	appropriate	HRP-conjugated	secondary	(1:10,000)	and	immunoreactive	bands	were	visualized	using	the	SuperSignal	West	Femto	kit	(Thermo	Scientific).		
Immunohistochemistry	Brains	and	spinal	cords	were	immunolabeled	as	previously	described	(Sato-Bigbee	et	al.,	1999;	Dupree	et	al.,	1999).	A	hydrophobic	barrier	was	formed	on	the	slide	around	the	tissue	using	a	PAP	pen	(abcam),	and	then	washed	several	times	to	remove	OCT.	Nonspecific	antibody	binding	was	blocked	by	incubation	of	the	tissue	on	slides	for	30	min	in	a	PBS	blocking	solution	containing	4%	cold	water	fish	skin	gelatin	(Electron	Microscopy	Sciences,	#25560)	and	0.5%	Triton-X,	which	was	used	in	all	subsequent	antibody	steps.	The	tissue	was	then	incubated	overnight	at	4oC	with	appropriate	primary	antibodies.	After	several	washes	in	PBS,	the	tissue	was	incubated	with	appropriate	secondary	antibodies	for	90	minutes.	After	several	washes,	slides	were	mounted	with	Vectashield™	(Vector	Laboratories,	Burlingame,	CA);	and	imaged	using	fluorescence	microscopy.	An	additional	antigen-retrieval	step	was	performed	for	APP	as	well	as	Ankyrin-G	staining	prior	to	the	
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above	blocking	step.	Tissue	was	incubated	in	a	citric	acid	buffer	(100mM	citric	acid	pH	6.0)	for	30min	at	45oC,	and	then	followed	by	three	consecutive	rinses	in	PBS.			
Microscopy/Quantification	AIS	analysis	Animals	were	actively	induced	with	EAE	and	sacrificed	42	days	post-induction.	All	images	were	collected	using	a	Zeiss	LSM	710	confocal	laser	scanning	microscope	(Carl	Zeiss	Microscopy)	housed	in	the	VCU	Department	of	Anatomy	and	Neurobiology	Microscopy	Facility.	Three	confocal	z-stacks,	each	spanning	an	optical	distance	of	15	μm,	using	a	pin	hole	of	1	Airy	disc	unit	and	Nyquist	sampling	were	collected	from	neocortical	layer	V	(-1.22	to	-1.94	from	bregma)	for	2	sections	per	mouse	resulting	in	6	images	per	animal	for	AIS	quantitation.	Images	were	taken	with	a	40X	oil-immersion	objective	with	a	numerical	aperture	of	1.3;	optical	slice	thickness	was	0.44	µm,	using	a	scan	average	of	2.		
X,	Y,	and	Z	image	dimensions	were	212.5	µm	×	212.5	µm	×	15.00	µm,	respectively.	The	gain	and	offset	values	were	kept	constant	for	all	images.	AISs	were	manually	traced	using	ImageJ	software	to	obtain	length	measurements	and	counts.	All	those	below	10	µm	in	length	or	sharing	the	border	of	the	X	and	Y	planes	were	excluded	(Benusa	et	al.,	2017).		Axonal	Degeneration	Quantification	Animals	were	actively	induced	with	EAE	and	sacrificed	42	days	post-induction.	Sequential	coronal	sections	of	lumbar	spinal	cords	from	Sarm1(-/-)	and	Sarm1(+/+)	animals	were	analyzed	using	fluorescent	microscopy.	Disruption	in	axonal	transport	of	proteins	such	as	APP	can	be	used	as	a	marker	of	axonal	injury.	Accumulation	of	APP	in	axonal	spheroids	is	a	
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reliable	marker	for	acute	axonal	damage.	Therefore,	we	used	APP	immunostaining	to	quantify	axonal	injury	in	lumbar	spinal	cords.	All	images	were	collected	using	a	Zeiss	AxioImager	Z2	(Carl	Zeiss	Microscopy)	equipped	with	a	Q-Imaging	Retiga-2000R	color	CCD	camera.	Six	representative,	nonoverlapping	images	from	a	coronal	lumbar	spinal	cord	section	were	taken	at	240	µm	intervals	throughout	the	spinal	cord	with	a	20x/.8NA	objective;	image	dimensions	were	580	µm	x	434	µm.	This	resulted	in	24	images	predominantly	of	the	lateral-most	spinocerebellar	tracts,	but	also	included	those	of	the	dorsal	column	and	spino-olivary	fibers.	The	gain	and	offset	values	were	kept	constant	for	all	images.	Total	APP	area	(µm2)	was	calculated	using	ImageJ	batch	analysis	software	after	manual	brightness	and	contrast	adjustments	(Benusa	et	al.,	2017).	Image	files	were	coded	to	blind	research	personnel	to	genotype	during	image	analysis.			Axonal	Transection	Quantification.	Animals	were	actively	induced	with	EAE	and	sacrificed	14	days	post-induction.	Sequential	coronal	sections	of	lumbar	spinal	cords	from	Sarm1(-/-)/Thy-1-YFP(+)	and	Sarm1(+/+)/	Thy-1-YFP	(+)	animals	expressing	YFP	within	axons	were	analyzed	using	fluorescent	microscopy.	All	images	were	collected	using	a	Zeiss	AxioImager	Z2	as	described	above.	Six	representative,	nonoverlapping	images	from	a	YFP-labeled	lumbar	spinal	cord	section	were	taken	at	240	µm	intervals	throughout	the	spinal	cord	with	a	20x/.8NA	objective;	image	dimensions	were	580	µm	x	434	µm.	This	resulted	in	24	images	predominantly	of	the	lateral-most	spinocerebellar	tracts,	but	also	included	those	of	the	dorsal	column	and	spino-olivary	fibers.	The	number	of	transected	axons	were	counted	using	ImageJ	software.	Three	equally-spaced,	perpendicular	lines	were	superimposed	on	the	images	and	the	number	of	
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intact	and	severed	axons	were	determined	based	on	the	number	of	YFP-labeled	axons	that	crossed	each	line.	Axons	spanning	multiple	vertical	lines	were	only	counted	once.		
	
Embryonic	Neuronal	Culture	Prior	to	dissection,	cell	culture	surfaces	were	coated	with	poly-D-lysine	(0.1 mg/mL;	Sigma-Aldrich)	and	appropriate	amounts	of	Neurobasal®	(NB;	Thermo	Fisher	Scientific)	media,	NB	media	+	glutamate,	and	NB	media	+	glutamate	+	trypsin/DNAse	were	prepared	as	previously	described	in	(Clark	et	al.,	2017).	Timed-pregnant	Sarm1(-/-)	and	Sarm1(+/+)	females	were	euthanized	when	pups	were	at	an	embryonic	age	of	15.5	days	using	isoflurane	overdose.	All	subsequent	dissections	were	performed	using	sterile	technique	in	a	laminar	flow	hood.	The	uterus	and	embryos	were	removed	and	washed	in	two	consecutive	steps	with	sterile	PBS.	The	embryos	were	dissected	from	the	amniotic	sacs	and	decapitated	prior	to	being	temporarily	stored	in	a	dish	containing	NB	media.	Three	brains	of	both	Sarm1(-/-)	and	Sarm1(+/+)	pups	of	were	then	removed	using	a	dissecting	microscope,	then	placed	individually	in	NB	media.	The	brains	were	split	into	two	hemispheres,	meninges	and	hippocampus	removed,	and	the	cerebral	cortex	was	dissected	and	placed	into	an	eppendorf	tube	containing	1	ml	of	NB	media.	The	cortex	fragments	were	then	washed	twice,	resuspended	in	NB	media	+	glutamate	+	trypsin/DNAse,	placed	in	a	37oC	incubator	on	a	preheated	rotator,	and	continually	rotated	for	30	minutes.	Cortex	fragments	were	then	centrifuged	at	300	x	g	for	2	minutes,	washed	twice	with	NB	medium,	and	resuspended	in	1ml	of	NB	media	+	glutamate.	A	single-cell	suspension	was	achieved	through	careful	trituration	followed	by	filtration	through	a	70	µm	filter	(J	Beaudoin	et	al.,	2012).	Cortical	neurons	were	then	counted	by	hemocytometer	and	cultured	on	poly-D-
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lysine-coated	plates.	Cortical	neuron	cultures	were	maintained	in	a	cell	culture	incubator	at	37oC,	with	NB	media	changes	every	72	hours	(DIV)	(Clark	et	al.,	2017).		
Fluorescence-activated	cell	sorting	(FACS)	analysis	Following	euthanasia,	animals	underwent	transcardiac	perfusion	with	up	to	50	ml	of	normal	saline	using	a	rate-controlled	pump.	Thoracolumbar	cords	(from	T2	to	caudal	end)	were	expelled	out	of	the	spinal	column	using	hydraulic	pressure	manually	applied	through	a	19-gauge	needle	and	syringe	filled	with	phosphate	buffered	saline	(PBS).	Cords	were	minced	using	a	McIlwaine	tissue	chopper	(Mickle	Laboratory	Eng.	Co.,	UK),	then	enzymatically	dissociated	in	RPMI	containing	2.5	mg/ml	collagenase	D	(Roche	Diagnostics,	Indianapolis,	IN)	and	DNaseI	(20	µg/ml,	Sigma	Aldrich)	for	45	minutes	at	37oC	on	a	rotator.	Cells	were	passed	through	a	70	µm	filter,	washed	in	RPMI,	resuspended	in	30%	isotonic	Percoll	(GE	Healthcare)	in	PBS,	then	centrifuged	at	500	x	g	for	10	min.	Supernatant	was	removed.	Cell	pellets	were	washed	and	resuspended	in	RPMI.	Cells	were	aliquoted	into	tubes	and	washed	in	FACS	buffer	(0.1%	sodium	azide	and	2%	fetal	calf	serum	in	PBS).	Cells	were	incubated	with	Fc	block	(anti-mouse	CD16/CD32	antibody,	BD	Biosciences)	for	5	minutes	prior	to	addition	of	fluorochrome-conjugated	antibodies	against	CD3	(clone	17A2),	CD4	(clone	GK1.5),	CD45	(clone	30-F11),	CD19	(clone	1D3),	CD8	(clone	53-6.7),	CD11b	(clone	M1/70),	CD11c	(clone	N418),	Ly6C	(clone	HK1.4),	Ly6G	(clone	1A8-Ly6G)	and	NK1.1	(clone	PK136).	Following	30-minute	incubation	in	the	dark	at	4oC,	cells	were	washed	in	FACS	buffer.	Count	beads	(CountBright,	Thermo	Fisher)	were	added	to	each	sample	to	allow	absolute	count	determination.	FACS	data	was	acquired	on	a	flow	cytometer	(FACS	Canto,	BD	Biosciences).	Data	were	analyzed	using	FlowJo	software	(FlowJo,	LLC).		
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HEK293	Cell	Culture/Transfection	HEK	293	cells	were	maintained	in	Dulbecco's	modified	Eagle's	medium	(DMEM)	supplemented	with	10%	(v/v)	heat-inactivated	fetal	bovine	serum	(FBS)	at	37°C	in	a	5%	CO2	humidified	atmosphere.	Transfection	was	performed	with	the	Lipofectamine™	3000	reagent	transfection	kit	(Invitrogen)	according	to	the	manufacturer's	instructions.	HEK293	cells	were	70%	confluent	at	time	of	transfection.	Immediately	prior	to	transfection,	1.5	µl	of	lipofectamine	3000	reagent	was	added	to	23.5	µl	of	opti-MEM™	(Thermofisher)	and	gently	vortexed	for	2-3	seconds.	In	a	separate	microcentrifuge	tube,	1µl	of	P3000	reagent	was	added	to	24	µl	of	opti-MEM	containing	DNA	500	ng	of	Sarm1	expression	vectors	for	bimolecular	fluorescence	as	detailed	in	Table	1.	The	diluted	DNA	+	P3000	reagent	was	added	to	the	lipofectamine	reagent	in	a	1:1	ratio,	and	the	solution	was	allowed	to	incubate	for	15	minutes	at	room	temperature	before	being	added	to	HEK293	cells	in	a	24-well	plate.	Cells	were	harvested	72	hours	later,	and	cell	lysate	analyzed	using	western	blot	for	presence	of	transgenic	SARM1	proteins	(Moreno	et	al.	2016).	
	
Western	Blot		Immunoblot	analysis	was	performed	according	to	the	method	described	previously	in	(Hazelton	et	al.	2009).	Following	transfection,	HEK293	cells	were	lysed	in	RIPA	lysis	buffer	(0.5	%	NONIDET	P-40,	1	%	Triton	X-100,	150	mM	NaCl,	10	mM	Tris	pH	7.4)	supplemented	with	protease	inhibitor	cocktail	(Sigma;	P8849).	The	BioRad	DC	protein	assay	was	used	to	determine	total	protein	concentration,	and	20	µl	of	total	cell	lysate	per	sample	was	resolved	on	4-20%	Mini-Protein®	TGX™	gels	and	transferred	to	polyvinylidene	fluoride	
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(PVDF)	membranes	(Invitrogen)	using	the	Trans-Blot®	Turbo™	System	(Bio-Rad).	The	membranes	were	washed	and	incubated	in	5%	non-fat	milk	in	phosphate-buffered	saline	with	0.05%	Tween	20	(PBST)	for	30	minutes,	then	incubated	overnight	at	4	°C	with	anti-human	SARM1	(Biolegend;	#696602;	1:250)	or	anti–GFP	(Novus	NB600-308SS;	1:1000)	under	continuous	agitation.	This	was	followed	by	washing	the	membranes	in	PBST	and	incubation	for	45	minutes	with	appropriate	HRP-conjugated	secondary	(1:10,000)	(Cell	Signaling	Technology)	antibody.	Immunoreactive	bands	were	visualized	using	the	SuperSignal	West	Femto	kit	(Thermo	Scientific)	(Peach	et	al.	2012).		
	
Statistical	Analysis	Mann–Whitney	was	used	for	two	group	comparisons.	Where	appropriate,	Kolmogorov-Smirnov	test	was	used	as	a	test	of	normality.	T-test	was	used	for	two	group	comparisons	for	normally	distributed	data.		Statistical	analysis	was	performed	using	Prism	software	(GraphPad).	
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Results	and	Discussion	The	contribution	of	SARM1-dependent	program	of	axonal	degeneration	to	the	pathophysiology	of	immune-mediated	CNS	inflammatory	disorders	was	previously	unknown.	Prior	studies	showed	that	the	loss	of	SARM1	was	beneficial	in	a	number	of	animal	models	of	neurological	disorders.	Sarm1	KO	mice	showed	reduced	clinical	severity	and	reduced	axonal	loss	in	an	animal	model	of	traumatic	brain	injury	(Henninger	et	al.	2016),	and	had	less	axonal	degeneration	in	animal	models	of	peripheral	neuropathy	due	to	chemotoxicity	or	metabolic	derangement	(Geisler	et	al.,	2016;	Turkiew	et	al.,	2017).	However,	loss	of	SARM1	had	no	significant	impact	on	axonal	loss	or	clinical	course	of	mutant	SOD1	model	of	amyotrophic	lateral	sclerosis	(Peters	et	al.,	2018).	Therefore,	the	contribution	of	SARM1	is	likely	to	be	disease-specific,	with	severity	and	duration	of	insult	potentially	dictating	the	therapeutic	potential	of	SARM1	inactivation.	In	this	thesis,	the	course	and	pathology	of	EAE	in	Sarm1-KO	mice	and	wild-type	littermates	were	compared	to	test	the	effect	of	SARM1	inactivation	on	axonal	degeneration	in	the	setting	of	chronic	immune-mediated	CNS	inflammation.	
Sarm1-KO	and	wild-type	littermates	were	actively	induced	to	undergo	EAE.	There	was	no	difference	in	the	incidence	of	EAE	between	Sarm1-KO	and	wild-type	littermates	(94%	vs.	100%,	p	>	0.99,	Fisher’	exact	test).	The	clinical	score	comparison	of	Sarm1-KO	and	wild-type	littermates	(Figure	1)	reflects	a	modest	reduction	in	motor	deficits	experienced	during	a	42-day	chronic	EAE	time	course.	While	peak	of	clinical	severity	and	onset	of	symptoms	were	similar,	there	was	a	divergence	in	mean	clinical	score	between	genotypes	beginning	at	about	3	weeks	post-induction.	From	that	point,	Sarm1-KO	mice	exhibited	a	faster	recovery	from	motor	deficits	than	wild-type	littermates	with	differences	in	score	
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becoming	statistically	significant	by	week	6.	Because	SARM1	is	expressed	in	neurons	as	well	as	immune	cells,	it	remained	to	be	clarified	whether	this	clinical	effect	was	attributable	to	loss	of	neuronal	SARM1,	immune	cell	SARM1	or	both.	Therefore,	additional	analysis	was	needed	to	clarify	the	mechanism	by	which	SARM1	inactivation	mediates	reduction	in	long-term	clinical	severity	in	EAE.	SARM1	expression	in	immune	cells	could	potentially	affect	the	course	of	CNS	inflammatory	disorders	based	on	its	N-terminal	TIR	domain	that	could	influence	immune	response	by	modulating	signaling	downstream	of	the	Toll-like	receptor	(TLR)	(Fekonja	et	al.,	2012).	To	address	this	question	of	whether	SARM1	TIR	domain	loss	had	an	impact	on	immune	cell	activation	and	subsequent	infiltration	into	the	CNS	during	EAE,	we	performed	FACS	analysis	of	CNS	infiltrating	immune	cells	during	the	peak	of	clinical	severity	(14	days	post-induction)	for	Sarm1-KO	and	wild-type	littermates	(Figure	2).	There	were	no	significant	differences	in	the	number	of	CNS	inflammatory	cells	between	Sarm1-KO	and	wild-type	littermates,	including	T	cells,	B	cells,	macrophage,	natural	killer	(NK)	cells	and	neutrophils,	suggesting	that	SARM1	inactivation	did	not	alter	inflammatory	cell	recruitment	into	the	CNS.	In	addition,	ex	vivo	antigen	(MOG35-55)	recall	response	data	from	our	laboratory	showed	no	difference	between	Sarm1-KO	and	wild-type	littermates	with	respect	to	peripheral	immune	activation	of	EAE	(data	not	shown).	These	results	are	consistent	with	the	clinical	observation	that	onset	and	incidence	of	EAE	are	comparable	between	the	genotypes.	It	remains	possible	that	CNS	immune	cell	infiltration	might	differ	between	Sarm1-KO	and	wild-type	littermates	at	later	time	points	and	it	may	be	informative	to	choose	a	later	time	point	to	determine	if	immune	infiltrates	correspond	to	the	divergence	in	clinical	score	at	week	3	post-induction	and	beyond.		
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Figure	1.	Clinical	course	of	EAE	in	Sarm1-KO	and	wild-type	littermates.	EAE	was	actively	induced	in	6-	to	10-week	old	Sarm1	KO	mice	(N	=	15;	7	females/8	males)	and	wild-type	littermates	(N	=	12;	7	females/5	males).	Mice	were	scored	daily	up	to	42	days	post-induction.	Animals	that	did	not	manifest	signs	of	EAE	by	day	14	post-induction	were	excluded.	*	p	<	0.05,	t-test.		 	
Figure 1:
Clinical score comparison of Sarm1-KO and wildtype littermates through chronic EAE course (42 
days post-induction).
EAE was actively induced in 6- to 10-week old Sarm1 [N = 15 (7F/8M) knockout ice and wild type 
littermates [N = 12 (7F/5M)]. Animals that did not manifest signs of EAE by day 14 post-induction 
were excluded. Mice were scored as follows: 0 – no overt signs of disease; 1 – limp tail or loss of 
righting reflex but not both; 2 – limp tail and loss of righting reflex; 3 – partial hind limb paralysis; 4 –
complete hind limb paralysis; 5 – moribund state or death. 
A
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Without	a	discernable	difference	in	immune	infiltrates	at	peak	EAE	disease	activity,	we	explored	the	effect	of	SARM1	inactivation	on	axonal	degeneration	through	analyses	of	AIS	morphology	in	layer	V	cortical	neurons,	axonal	transport	disruption,	and	transection	in	the	lumbar	spinal	cord.	These	analyses	were	designed	to	measure	neuroprotective	effects	of	SARM1	loss,	relative	to	a	SARM1-dependent	program	of	axonal	degeneration,	broadly	across	the	CNS	at	various	disease	time	points.		AIS	of	layer	V	primary	somatosensory	cortex	was	previously	shown	to	be	vulnerable	in	EAE	(Clark	et	al.,	2016).	To	determine	whether	AIS	loss	in	EAE	could	be	ameliorated	by	
Sarm1-KO,	we	quantified	AIS	in	the	layer	V	primary	somatosensory	cortex	by	immunohistochemistry.	We	found	no	significant	difference	between	Sarm1-KO	and	WT	littermates	with	respect	to	AIS	length	or	total	AIS	count	within	layer	V	of	the	primary	somatosensory	cortex	(-1.2	to	-1.9	Bregma)	at	42	days	post-induction	(Figure	3).	It	has	been	reported	that	disruption	in	AIS	organization	in	EAE	is	not	the	consequence	of	demyelination,	neuronal	death	or	axonal	transection,	but	is	associated	with	reactive	microgliosis	(Clark	et	al.,	2016).	Prior	research	also	indicated	that	AIS	loss	in	EAE	corresponded	to	severity	of	clinical	scores	(Clark	et	al.,	2016).	One	possible	interpretation	of	our	result	is	that	SARM1	does	not	contribute	to	AIS	loss	in	EAE.	We	have	not,	however,	ruled	out	the	possibility	that	EAE	did	not	result	in	substantial	AIS	loss	in	our	experiments.	It	remains	possible	that	there	may	have	been	insufficient	disease	activity	in	our	experimental	animals	to	result	in	substantial	AIS	loss.	A	greater	number	of	animals	with	clinical	scores	of	3	and	above	that	extend	into	the	3rd	week	post-induction	may	be	necessary	to	see	a	greater	effect.	Future	experiments	will	include	additional	control	animals	(mice	immunized	with	only	CFA	at	induction)	to	confirm	AIS	loss	in	our	
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experimental	animals.	Future	analyses	will	also	include	measures	of	microglial	activation	in	layer	V	cortex	to	provide	information	on	the	presence	or	absence	of	cortical	inflammation	in	our	experimental	animals.		 	
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Figure	2.	CNS	inflammatory	infiltrates	in	Sarm1-KO	and	wild-type	littermates	at	peak	
of	EAE	clinical	severity.	Thoracolumbar	cords	from	Sarm1-KO	and	wild-type	littermates	at	day	14	post	induction	were	enzymatically	dissociated	into	single-cell	suspension	then	analyzed	by	FACS.	Cells	were	identified	by	immunophenotypic	markers	as	microglia	(CD45lo,	CD11c+,	CD11b+),	macrophage	(CD45+,	CD11b+,	CD11c+,	Ly6c+),	total	T	cells	(CD3+),	T	helper	cells	(CD3+,CD4+),	cytotoxic	T	cells	(CD3+,CD8+),	B	cells	(CD19+),	natural	killer	cells	(NK1.1+),	neutrophils	(Ly6GHi,	CD11b+).	Shown	are	absolute	counts	for	Sarm1-KO	(circle)	and	wild-type	(square)	for	the	indicated	immune	cell	types.		
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Figure	3.	Axon	initial	segment	(AIS)	number	and	length	in	layer	V	cortical	neurons	of	
Sarm1-KO	and	wild-type	littermates	during	chronic	EAE	(42	days	post-induction).		A)	Representative	maximum	intensity	projection	of	Sarm1(-/-)	mouse	(S1BF	-1.68	Bregma).	B)	Representative	maximum	intensity	projection	of	wild-type	Sarm1(+/+)	mouse	(S1BF	-1.94	Bregma).	C)	Quantification	of	mean	AIS	length.	D)	Quantification	of	total	AIS	count	(n=9;	6	images	per	animal).		
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As	previously	mentioned,	inflammatory	lesions	in	EAE	models	are	predominantly	located	within	the	spinal	cord,	whereas	in	MS	CNS	inflammation	involves	both	brain	and	spinal	cord.	However,	EAE	pathology	in	the	lumbar	spinal	cord	can	still	serve	as	a	sufficient	model	for	inflammation-induced	axonal	injury	similar	to	what	is	seen	in	white	matter	lesions	of	MS.	This	is	especially	relevant	as	past	studies	identified	axonal	damage	in	the	form	of	altered	axonal	trafficking	and	axonal	transection	within	inflammatory	MS	lesions	as	a	major	determinant	of	disability	accumulation	(Trapp	et	al.,	1999;	Singh	et	al.,	2017).		Disruption	in	axonal	transport	of	proteins	such	as	APP	can	be	used	as	a	marker	of	axonal	injury.	Accumulation	of	APP	in	axonal	spheroids	is	a	reliable	marker	for	acute	axonal	damage	(Schultz	et	al.,	2017).	Therefore,	we	used	immunostaining	to	quantify	axonal	injury	in	lumbar	spinal	cords	of	Sarm1-KO	and	wild-type	littermates	(42	days	post-induction).	There	was	a	decrease	in	mean	APP	area	(µm2)	observed	in	Sarm1-KO	mice	compared	to	wild-type	littermates	that	did	not	reach	statistical	significance	(Figure	4,		p	=	.31,	Mann-Whitney).	One	possible	interpretation	is	that	SARM1	loss	resulted	in	a	modest	reduction	in	inflammation-induced	axonal	damage	that	requires	a	larger	sample	size	to	detect	a	statistically	significant	difference.	Sample	size	calculation	indicated	that	N	of	20	in	each	arm	would	be	required	to	detect	a	statistically	significant	difference	of	this	magnitude	with	80%	power	(β	=	0.2).	Because	SARM1	has	been	characterized	as	the	final	executioner	of	axonal	degeneration,	one	could	hypothesize	that	axons	lacking	SARM1	would	have	a	greater	possibility	of	recovery	after	injury.	However,	this	also	means	that	there	could	potentially	be	a	greater	number	of	axons	existing	in	this	state	(that	are	APP+)	at	a	given	time,	as	Sarm1	deletion	has	been	shown	to	suppress	Wallerian	degeneration	for	weeks	(Henninger	et	al.,	2016).	While	there	is	a	modest	decrease	in	mean	APP	area,	
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potentially	attributed	to	indirect	anti-inflammatory	benefits	from	decreased	cellular	debris	and	microglial	activation,	it	may	not	be	fully	representative	of	the	direct	neuroprotective	benefits	SARM1	loss	confers.		
	
Figure	4.	Axonal	degeneration	and	impaired	axonal	transport	in	Sarm1-KO	and	wild-
type	littermates	during	chronic	EAE	as	revealed	by	amyloid	precursor	protein	(APP)	
accumulation	(42	days	post-induction).	A)	Representative	images	of	Sarm1(-/-)	mouse	(lumbar	spinocerebellar	tract).	B)	Representative	images	of	wild-type	Sarm1(+/+)	mouse	(lumbar	spinocerebellar	tract).	C)	Mean	total	area	(µm2)	of	APP	by	genotype	(n=5;	24	images	per	animal).			
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Measuring	the	difference	in	percent	transected	axons	between	genotypes	offers	another	measure	to	analyze	the	effect	SARM1	loss	on	axonal	degeneration.	Therefore,	
Sarm1-KO	and	wild-type	mice	were	crossed	with	Thy1-YFP	mice	that	express	yellow	fluorescent	protein	(YFP)	in	motor,	sensory,	and	subsets	of	central	neurons.	These	YFP-labeled	axons	in	the	lumbar	spinal	cords	of	Sarm1(-/-)/YFP(+)	and	Sarm1(+/+)/	YFP(+)	mice	were	analyzed	at	peak	of	EAE	clinical	severity	(day	14	post-induction).	There	was	a	marked	decrease	in	percentage	of	transected	axons	in	Sarm1-KO	mice	when	compared	to	wild-type	mice	(Figure	5).	This	result	suggests	that	the	loss	of	SARM1	may	be	particularly	protective	against	axon	degeneration	during	the	early	course	of	EAE,	but	more	samples	are	needed	to	test	for	statistical	significance.	It	would	be	of	interest	to	examine	axonal	degeneration	using	the	Thy1-YFP	mice	at	later	time	points	in	EAE	to	determine	whether	such	measures	of	axonal	degeneration	correlate	with	the	divergence	in	clinical	score	observed	in	the	latter	part	of	the	chronic	42-day	EAE	time	course.	In	the	future,	it	would	be	of	interest	to	extend	the	chronic	EAE	time	course	to	see	if	there	are	more	pronounced,	permanent	differences	in	clinical	score	between	genotypes.	This	could	be	facilitated	by	cognitive	behavioral	and/or	motor	skill	tests	prior	to	EAE	induction	and	retesting	following	EAE	resolution.	This	would	allow	for	a	more	translational	representation	of	the	therapeutic	advantages	of	SARM1	inactivation	in	MS	and	other	neuroinflammatory	disorders.		
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Figure	5.	Axonal	degeneration	of	EAE	in	Sarm1-KO/YFP+	and	Sarm1(+/+)/	YFP+	
littermates.		Sarm1(-/-)/Thy-1-YFP(+)	and	Sarm1(+/+)/	Thy-1-YFP	(+)	mice	were	actively	induced	to	undergo	EAE.	Lumbar	cords	from	the	mice	were	imaged	at	day	14	post	induction	(peak	of	EAE	clinical	severity).	A)	Representative	image	of	Sarm1(-/-)/Thy-1-YFP(+)	mouse.	B)	Representative	image	of	Sarm1(+/+)/	Thy-1-YFP	(+)	mouse.	C)	Mean	percent	of	transected	axons	by	genotype	(n=2	per	genotype;	24	images	per	animal).			
	
	
BA
C
SARM1-KO WT
0.0
0.1
0.2
0.3
0.4
0.5
0.6
%
 T
ra
ns
ec
te
d 
ax
on
s
YFP DAPIYFP DAPI
Sarm1-KO WT 
 32 
	
Sarm1	Bimolecular	Fluorescence	Complementation		The	functional	domains	of	SARM1	(Figure	6B)	have	been	well	characterized.	The	two	tandem	sterile	alpha	motifs	(SAM)	are	responsible	for	multimerization	and	the	C-terminus	Toll/Interleuken-1	receptor	(TIR)	domain	functions	to	mediate	NADase	activity	of	SARM1	(Gerdts	et	al.,	2013).	The	N-terminal	armadillo/HEAT	motif	(ARM)	domain	has	been	shown	to	be	autoinhibitory	through	interaction	with	the	TIR	domain	(Summers	et	al.	2016).	However,	there	is	still	much	to	be	learned	regarding	the	upstream	signaling	of	SARM1	activation.	A	molecular	tool	for	in	situ	detection	of	SARM1	activation	would	allow	for	a	detailed,	mechanistic	approach	to	advance	our	understanding	of	SARM1	activation.		 Figure	6A	depicts	bimolecular	fluorescence	complementation	(BiFC),	a	process	by	which	fluorescence	is	restored	when	two	non-fluorescent	fragments	of	a	fluorescent	protein	such	as	mCitrine	are	brought	into	close	proximity	via	fusion	to	proteins	that	undergo	protein-protein	interaction.	This	concept	was	applied	to	SARM1	as	a	means	of	detecting	activation	in	situ	via	mCitrine	fluorescence.	DNA	coding	for	two	fragments	of	mCitrine	(–N172	and	–C67)	were	individually	cloned	into	the	pcDNA3.1	vector	downstream	of	human	Sarm1	open	reading	frame	sequence	(Figure	6C).	This	resulted	in	SARM1	proteins	C-terminally	fused	to	complementary	fragments	of	mCitrine.	Figure	6D	illustrates	our	hypothesis	that	two	SARM1-mCitrine	fragment	fusion	proteins	are	conformationally	inhibited	from	BiFC	when	SARM1	is	in	its	inactive	configuration.	Relief	of	intramolecular	ARM	inhibition	is	predicted	to	allow	TIR	domain	dimerization	and	mCitrine	complementation	and	fluorescence.		
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Figure	6.	SARM1	bimolecular	fluorescence	complementation	(BiFC)	A)	Cartoon	illustrating	bimolecular	fluorescence	complementation	(BiFC).	Fluorescence	is	restored	in	non-fluorescent	fragments	of	mCitrine	when	the	fragments	are	brought	together	by	fusion	of	two	proteins	that	undergo	protein-protein	interaction.	B)	Schematic	diagram	of	SARM1	functional	domains.	From	left	to	right:	mitochondrial	localization	signal	(MLS),	an	autoinhibitory	N-terminus	region	consisting	of	armadillo/HEAT	motifs	(ARM),	two	sterile	alpha	motifs	(SAM)	responsible	for	multimerization,	and	a	C-terminus	Toll/Interleuken-1	receptor	(TIR)	domain	with	NADase	activity	when	dimerized.	C)	Plasmid	map	illustrating	the	DNA	sequence	for	a	SARM1-mcitrine	fusion	protein	cloned	into	the	pcDNA3.1	expression	vector.	D)	Cartoon	depicting	two	SARM1	proteins	each	with	different	complementary	fragment	of	mCitrine	fused	to	the	TIR	domain	in	an	inactive	dimer	configuration.	E)	Cartoon	depicting	above	mentioned	SARM1	proteins	in	active	configuration	restoring	non-fluorescent	fragments	of	mCitrine	with	NADase	activity.		
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	 The	first	step	in	development	of	a	SARM1	BiFC	assay	was	confirming	the	protein	products	of	the	cloned	expression	vectors	in	a	eukaryotic	system.	Several	variations	of	the	two	aforementioned	SARM1-BiFC	constructs	were	also	created	as	controls	using	the	same	pcDNA3.1	expression	vector	(Figure	7C).	These	included	plasmids	encoding	mutant	Sarm1	lacking	the	N-terminal	auto-inhibitory	domains,	theoretically	making	the	corresponding	SARM1	dimer	constitutively	active	and	fluorescent;	complementary	mCitrine	fragments	individually	cloned	without	Sarm1;	a	full-length	Sarm1	without	mCitrine,	but	with	a	FLAG-tag	(DYKDDDDK	epitope);	and	finally,	a	full-length	mCitrine	without	Sarm1.	HEK293	cells	were	transfected	with	SARM1-mCitrine	expression	vectors	using	lipofection,	cells	were	collected	72	hours	later	and	cell	lysates	analyzed	via	western	blot.	Depending	on	the	BiFC	expression	vector,	protein	products	were	visualized	with	anti-GFP	(Figure	7A)	and/or	anti-SARM1	(Figure	7B)	antibodies.	The	SARM1-mCitrine	BiFC	fusion	proteins	depicted	in	Figure	6	were	both	confirmed	using	their	molecular	weight	by	antibodies	directed	against	SARM1	and	GFP.	Additional	obstacles	regarding	effective	transfection	and	expression	of	these	plasmids	in	neurons	still	exist.	Experiments	to	optimize	gene	dosage	to	ensure	proper	copy	number	and	localization	within	neurons	is	still	needed	as	well.	Stereological	administration	using	a	viral	vector	such	as	a	recombinant	adeno-associated	virus	(AAV)	could	allow	for	more	precise	control	over	these	factors,	mitigate	damage	to	transfected	neurons,	and	allow	for	broad	dissemination	within	the	CNS	and	to	neuronal	cultures.	
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Figure	7.	SARM1-BiFC	proteins	expressed	in	HEK293	cells.	HEK293	cells	were	transfected	with	SARM1-BiFC	expression	vectors,	cells	were	collected	72	hours	later	and	cell	lysates	analyzed	via	western	blot.	Depending	on	the	BiFC	expression	vector,	protein	products	were	visualized	with	anti-GFP(A)	and/or	anti-SARM1(B)	antibodies.	A)	All	GFP-containing	SARM1-BiFC	protein	products	and	controls	were	confirmed	based	on	expected	molecular	weight	(with	exception	of	the	C-terminal	67-amino-acid	fragment	of	mCitrine).	B)	Each	SARM1	protein	with	different	complementary	fragment	of	mCitrine	(–N172	and	–C67)	was	confirmed	based	on	expected	molecular	weight.	C)	List	of	SARM1-BiFC	expression	vectors	and	controls	depicted	in	above	western	blot	with	corresponding	molecular	weights.					
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When	assessing	the	therapeutic	potential	of	SARM1	in	MS,	the	heterogeneous	nature	of	the	various	clinical	courses	in	humans	and	how	well	the	severity	and	duration	of	MS	compares	in	mouse	models	must	be	considered.	Even	though	a	chronic	model	of	EAE	was	used	in	a	majority	of	analyses,	the	largely	monophasic	disease	course,	and	that	a	majority	of	pathology	is	observed	in	the	spinal	cord	may	have	obscured	some	benefits	that	SARM1	inactivation	may	impart	during	MS.	However,	the	inflammation-induced	axonal	pathology	observed	in	the	lumbar	spinal	cord	is	still	relevant	to	both	relapsing-remitting	and	progressive	courses	of	MS.	The	reduction	in	the	severity	of	EAE	in	Sarm1-KO	compared	to	wild-type	mice	reflected	in	statistically	significant	reduction	in	clinical	scores	coupled	with	reduction	in	axonal	degeneration	and	transection	is	a	key	benchmark	for	identifying	SARM1	as	a	rational	therapeutic	target	in	the	treatment	of	neuroinflammatory	disorders.		Currently	there	are	no	pharmacological	interventions	to	inactivate	SARM1	in	such	disorders,	only	a	theoretical	gene	therapy	using	viral	vectors	to	deliver	SARM1	dominant-negatives	that	block	axonal	degeneration	following	axotomy	(Geisler	et	al.,	2019).	However,	the	proposed	SARM1-BiFC	assay	has	the	potential	to	eventually	screen	for	compounds	that	modulate	SARM1	activity	as	well	as	uncover	novel	therapeutic	targets	upstream	of	SARM1	as	our	understanding	of	upstream	signaling	pathways	improves.		
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